DSpace Repository

Triclabendazole for the treatment of human fascioliasis and the threat of treatment failures

Show simple item record

dc.contributor.author Marcos, L.
dc.contributor.author Maco, V.
dc.contributor.author Terashima, A.
dc.date.accessioned 2021-10-04T23:01:01Z
dc.date.available 2021-10-04T23:01:01Z
dc.date.issued 2021
dc.identifier.uri https://hdl.handle.net/20.500.12866/9903
dc.description.abstract Introduction: The only drug effective against the infection caused by Fasciola hepatica or F. gigantica is triclabendazole (TCBZ), recommended by the WHO and recently approved by the FDA. Here, we describe the evolution of TCBZ regimens and the emergence of TCBZ failure to Fasciola infection. Areas covered: The present review focuses on the evidence of TCBZ for the treatment of fascioliasis. For acute fascioliasis, there is a lack of studies to measure the presence of eggs of Fasciola in stool samples on the follow-up after initial TCBZ treatment. For chronic fascioliasis, WHO recommends a single oral dose of TCBZ 10 mg/kg whereas CDC recommends two doses of TCBZ 10 mg/kg 12 h apart. Incremental number of treatment failures have been documented worldwide. There are currently no therapeutic alternatives for the treatment of fascioliasis in humans. Expert opinion: Most cases of human fascioliasis are successfully treated with TCBZ, but some continue excreting eggs in the stools despite 1–2 standard of care regimens of TCBZ. A precise regimen is unclear for those patients who fail the initial treatment with TCBZ. Further clinical trials are needed to address the possible TCBZ emerging resistance en_US
dc.language.iso eng
dc.publisher Taylor and Francis
dc.relation.ispartofseries Expert Review of Anti-Infective Therapy
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject clinical trials en_US
dc.subject efficacy en_US
dc.subject Fasciola en_US
dc.subject neglected tropical disease en_US
dc.subject resistance en_US
dc.subject treatment failure en_US
dc.subject triclabendazole en_US
dc.title Triclabendazole for the treatment of human fascioliasis and the threat of treatment failures en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.1080/14787210.2021.1858798
dc.relation.issn 1744-8336


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics